Biotechnology company developing immuno-oncology therapies to treat cancer.
Agenus Inc., headquartered in Lexington, Massachusetts, is a pioneering clinical-stage immuno-oncology company that focuses on discovering and developing advanced products designed to combat cancer both in the United States and globally. The company is renowned for its innovative Retrocyte Display platform, which facilitates the identification of fully human and humanized monoclonal antibodies, alongside other proprietary display technologies.
Agenus Inc. boasts a robust pipeline of vaccine programs that include the Prophage vaccine candidate and QS-21 Stimulon adjuvant, a saponin-based enhancer for vaccine efficacy. The company's portfolio also features a range of cutting-edge antibody therapies, such as Balstilimab, an anti-PD-1 antagonist that has completed Phase II trials for treating second-line cervical cancer.
Continuing its trailblazing efforts, Agenus Inc. is advancing several promising therapies through clinical trials. These include AGEN1181, an anti-CTLA-4 monospecific antibody in Phase 1/2 trials, and AGEN2373, an anti-CD137 monospecific antibody undergoing Phase 1 trials. Additionally, Agenus is developing AGEN1423, a bi-functional antibody targeting CD73/TGFß TRAP, which has completed Phase 1 trials.
Under various trademarks like ASV, AutoSynVax, MiNK, Prophage, and others, Agenus Inc. collaborates with industry leaders such as Incyte Corporation, Merck Sharp & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. These partnerships enhance its capabilities in expanding therapeutic solutions across multiple cancer types and advancing the forefront of immuno-oncology research and development. Founded in 1994 as Antigenics Inc. and rebranded in January 2011, Agenus Inc. continues to innovate and drive progress in the fight against cancer.